Abstract
Between 30%-40% of patients with prostate cancer experience disease recurrence following radical prostatectomy. Existing clinical models for recurrence risk prediction do not account for population-based variation in the tumor phenotype, despite recent evidence suggesting the presence of a unique, more aggressive prostate cancer phenotype in African American (AA) patients. We investigated the capacity of digitally measured, population-specific phenotypes of the intratumoral stroma to create improved models for prediction of recurrence following radical prostatectomy. This study included 334 radical prostatectomy patients subdivided into training (VT, n = 127), validation 1 (V1, n = 62), and validation 2 (V2, n = 145). Hematoxylin and eosin-stained slides from resected prostates were digitized, and 242 quantitative descriptors of the intratumoral stroma were calculated using a computational algorithm. Machine learning and elastic net Cox regression models were constructed using VT to predict biochemical recurrence-free survival based on these features. Performance of these models was assessed using V1 and V2, both overall and in population-specific cohorts. An AA-specific, automated stromal signature, AAstro, was prognostic of r...Continue Reading
References
Nov 1, 1994·The Journal of Urology·H ZinckeD M Barrett
May 30, 1998·Journal of the National Cancer Institute·M W KattanP T Scardino
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey H BurkhardtJames A Hayman
Nov 16, 2004·Nature Genetics·John P A IoannidisThomas A Trikalinos
Jan 18, 2005·Seminars in Cancer Biology·Mark S Condon
Jul 28, 2005·JAMA : the Journal of the American Medical Association·Stephen J FreedlandAlan W Partin
Feb 20, 2008·Neoplasia : an International Journal for Oncology Research·Scott A TomlinsArul M Chinnaiyan
May 13, 2010·Scandinavian Journal of Urology and Nephrology·Davor TomasBozo Kruslin
Mar 1, 2009·Population and Development Review·Anthony Daniel Perez, Charles Hirschman
Jul 24, 2010·Journal of Translational Medicine·Amy E RoseIman Osman
Nov 26, 2010·The Journal of Clinical Investigation·Ankur SharmaKaren E Knudsen
Mar 2, 2011·PloS One·Carolina BonillaRick A Kittles
Jun 8, 2011·Cancer·Matthew R CooperbergPeter R Carroll
Nov 11, 2011·Science Translational Medicine·Andrew H BeckDaphne Koller
Jun 12, 2013·International Journal of Cancer. Journal International Du Cancer·Matthew A KinsethKathleen L McGuire
Feb 8, 2014·PloS One·Christina HägglöfAnders Bergh
Aug 27, 2016·Journal of Pathology Informatics·Andrew Janowczyk, Anant Madabhushi
Jan 25, 2017·Cancers·Damien A Leach, Grant Buchanan
Jul 30, 2017·European Urology Focus·George LeeAnant Madabhushi
Sep 6, 2017·Nature Communications·Svitlana TyekuchevaMassimo Loda
Feb 21, 2018·Nature Reviews. Urology·Tamara JamaspishviliTamara L Lotan
Feb 24, 2018·Carcinogenesis·Bethtrice ElliottShafiq A Khan
Jan 9, 2019·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
May 22, 2019·The Prostate·Rajal B ShahWei Tian
Aug 11, 2019·Nature Reviews. Clinical Oncology·Kaustav BeraAnant Madabhushi
Citations
Sep 4, 2020·Current Opinion in Urology·Victor M SchuettfortShahrokh F Shariat
Nov 10, 2020·JCO Clinical Cancer Informatics·Kaustav BeraAnant Madabhushi
Feb 17, 2021·Nature Biomedical Engineering·Jonathan T C LiuAnant Madabhushi
Apr 4, 2021·Cancer Discovery·Bhavneet BhinderOlivier Elemento